Vantage logo

Albireo comes up to IBAT in Nash

Albireo is taking aim at yet another Nash target, but Shire and Glaxosmithkline have already ditched projects with similar mechanisms.

Vantage logo

Orphazyme tries its luck 

Despite missing pretty much all the endpoints of a registrational study, the Danish company insists that it has a chance of approval for a treatment for an incurable…